Ecallantide clinical trials
Also written DX-88.
How each study uses ecallantide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 1 Dec 2009 · KALBITOR · BLA 125277 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Shire (6) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · Fovea Pharmaceuticals SA (1)
Studies
Open first, then newest update. How each study uses ecallantide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedPhase 3ShireNCT00262080Written as ecallantide
- Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced AngioedemaTerminatedPhase 2ShireNCT01343823Written as ecallantide 60 mg
- Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)CompletedPhase 3ShireNCT00456508Written as ecallantide
- Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedPhase 3ShireNCT00457015Written as ecallantide
- EDEMA2: Evaluation of DX-88's Effect in Mitigating AngioedemaCompletedPhase 2ShireNCT01826916Written as DX-88 (ecallantide)
- Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary AngioedemaWithdrawnPhase 2/3ShireNCT01253382Written as ecallantide
- Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/ReplacementTerminatedPhase 2Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00448864Written as Ecallantide
- A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss VolumeCompletedPhase 2Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00816023Written as ecallantide
- Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac SurgeryCompletedPhase 2Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00888940Written as Ecallantide
- Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein OcclusionTerminatedPhase 1Fovea Pharmaceuticals SANCT00969293Written as FOV2302 (Ecallantide)
Codes
What other systems call ecallantide · ClinicalTrials.gg INT004925
- MeSH (NLM) C511194ecallantideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5Q6TZN2HNMECALLANTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 658708Confirmed FDA, Wikidata
- Wikidata Q1280166ecallantideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65505EcallantideConfirmed FDA, Wikidata
- DrugBank DB05311One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C511194 | ecallantide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5Q6TZN2HNM | ECALLANTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 658708 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1280166 | ecallantide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65505 | Ecallantide | Confirmed FDA, Wikidata |
| DrugBank | DB05311 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.